• Info
  • Insider Ownership

Insider Trading & Ownership of David S. Grayzel

Location
Cambridge, MA
Summary
The estimated net worth of David S. Grayzel is at least $50,898,004 dollars as of 30 Jan 2026. David S. Grayzel is the Director of Aerovate Therapeutics, Inc. and owns shares of Jade Biosciences, Inc. (JBIO) stock worth about $50.85M. David S. Grayzel is the Director of Q32 Bio Inc. and owns shares of Q32 Bio Inc. (QTTB) stock worth about $45K.
Signature
/s/ Eric Bell, Attorney-in-Fact
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow David S. Grayzel and return when a new Insider Trading filing appears.

This tracks SEC filing changes for this page using existing product update flows.

Sign up to follow filing activity

Sponsored

Quick Takeaways

  • David S. Grayzel has 3 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $50,898,004.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: Aerovate Therapeutics, Inc. ($50,853,006).
  • Past-year value change for that position: .

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Official SEC Source

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of David S. Grayzel

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
JBIO Aerovate Therapeutics, Inc. Director $50,853,006 05 Jun 2024
QTTB Q32 Bio Inc. Director $44,998 15 Jan 2026
SURF Surface Oncology, Inc. Director 08 Sep 2023

Insider Transactions Reported by David S. Grayzel:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sponsored